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CASE PRESENTATION
A 56-year-old woman who never smoked presented with 
left supraclavicular lymphadenopathy. A computed tomogra-
phy (CT) scan revealed a lung tumor in the left upper lobe 
and mediastinal lymphadenopathies. Biopsy of the supracla-
vicular lymph node confirmed non–small-cell lung cancer 
(NSCLC) with a poorly differentiated tumor histology favor-
ing adenocarcinoma. The results of a bone scan and head CT 
scan were negative for metastases, and the patient was con-
sidered to have T1N3M0 stage IIIB disease. She received 
first-line platinum-based chemotherapy concurrent with tho-
racic radiotherapy and achieved a complete response. Twenty 
months after completion of chemoradiotherapy, the patient 
presented with recurrent disease in the form of a brain metas-
tasis, which was treated with γ-knife radiotherapy. However, 
4 months later, a positron emission tomography–CT scan 
showed multiple lymph node metastases affecting mediasti-
nal, contralateral hilar, and para-aortic lymph nodes (Fig. 1A, 
arrows), and a head CT scan revealed asymptomatic recur-
rence of brain metastasis, which was a progression of the 
previously identified central nervous system lesion that was 
treated with γ-knife radiotherapy (Fig. 2A). Mutation analy-
sis of the biopsy of tumor tissue at diagnosis showed that the 
tumor was wild type for the epidermal growth factor receptor 
(EGFR) gene. Fluorescence in situ hybridization analysis with 
break-apart probes for the anaplastic lymphoma kinase (ALK) 
gene, however, revealed the presence of an ALK rearrange-
ment. Crizotinib (250 mg twice daily) was administered orally 
with no clinically relevant adverse effects. After 3 weeks of 
crizotinib therapy, a repeat head CT scan showed a marked 
decrease in the size of the contrast-enhanced lesion in the 
frontal lobe and amelioration of surrounding edema (Fig. 2B). 
A repeat positron emission tomography–CT scan revealed 
that the mediastinal, contralateral hilar, and para-aortic 
lymphadenopathies had almost completely resolved (Fig. 1B). 
A follow-up CT scan of the brain performed after 11 months 
of crizotinib therapy showed complete resolution of the brain 
metastasis. The patient is currently still receiving crizotinib 
therapy with no evidence of progression on regular follow-up 
every 3 to 6 weeks.
DISCUSSION
The development of brain metastases from NSCLC is a chal-
lenging clinical problem, having an adverse impact on qual-
ity of life and survival. Given that chemotherapy is only 
moderately beneficial for such metastases, brain radiotherapy 
remains a standard palliative treatment. Crizotinib is the first 
ALK tyrosine kinase inhibitor to become clinically available 
and has shown marked and durable efficacy for the treatment 
of NSCLC positive for ALK rearrangement. It is considered to 
have a limited role in the treatment of brain metastases, how-
ever, as a result of its poor penetration of the blood–brain bar-
rier.1,2 Indeed, the sole site of initial progressive disease is the 
brain in patients with ALK rearrangement–positive NSCLC 
treated with crizotinib. The present patient was diagnosed 
with ALK rearrangement–positive NSCLC and manifested 
pronounced and rapid regression of a brain metastasis only 3 
weeks after initiation of crizotinib treatment. To our knowl-
edge, this is the first report of a marked effect of crizotinib on 
a brain metastasis derived from ALK rearrangement–positive 
NSCLC. Crizotinib, which is also a potent inhibitor of the tyro-
sine kinase MET, was recently shown to induce regression of 
glioblastoma positive for MET amplification.3 It is thus note-
worthy that crizotinib has been proven effective for the treat-
ment of both primary and metastatic brain tumors despite its 
limited ability to penetrate the blood–brain barrier. Previous 
studies have also documented the effectiveness of EGFR tyro-
sine kinase inhibitors such as gefitinib and erlotinib for the 
treatment of brain metastases of NSCLC positive for activating 
EGFR mutations, again despite the relatively low permeability 
of the blood–brain barrier to these drugs.4 Our present case 
indicates that crizotinib can be effective for the treatment of 
brain metastasis in a subset of patients with ALK rearrange-
ment–positive NSCLC in a manner similar to EGFR inhibitors 
in patients with NSCLC positive for EGFR mutation.
The present report provides insight into the efficacy of 
crizotinib for the treatment of brain metastasis in crizotinib-
naive patients with ALK rearrangement–positive NSCLC. 
Further investigation to define the clinical benefit of crizotinib 
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for the treatment of brain metastasis in this patient population 
is thus warranted.
CONSENT
Written informed consent was obtained from the patient for 
publication of this case report and accompanying images.
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FIGURE 1.  PET-CT imaging before and after crizotinib treat-
ment. (A) PET-CT scan before treatment revealing multiple 
lymph node metastases affecting mediastinal, contralateral 
hilar, and para-aortic lymph nodes (arrows). (B) PET-CT scan 
3 weeks after initiation of crizotinib therapy showing almost 
complete resolution of the multiple lymph node metas-
tases. PET-CT, positron emission tomography–computed 
tomography.
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FIGURE 2.  Head CT scans before and after crizotinib treat-
ment. (A) Head CT scan before treatment showing a single 
brain metastatic lesion with surrounding edema in the right 
frontal lobe. (B) Head CT scan 3 weeks after the initiation of 
crizotinib therapy revealing a marked decrease in size of the 
contrast-enhanced lesion and amelioration of the surround-
ing edema. CT, computed tomography.
